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Dialysis time, survival, and
dose-targeting bias
John T. Daugirdas1
Dialysis time is increasingly being appreciated as an important measure
of dialysis adequacy. Increased dialysis time leads to better control of
volume excess, to reduced occurrence of intradialytic hypotension, and
to better control of serum phosphorus. Nevertheless, the amount of
benefit obtainable by moderate increases in dialysis time in patients
following a three-times-per-week schedule has not been well
established, and the analysis is confounded by associations between
prescribed and/or delivered dialysis time and factors related to patient
mortality.
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In this issue of Kidney International,
analyzing a cohort of prevalent patients
being dialyzed mostly three times per
week with 3- to 5-hour session lengths,
Flythe et al.1 report on the association
between prescribed dialysis treatment
time and survival. They found a subs-
tantial mortality increase associated with
slightly shorter prescribed session length.
Controlling for body size is impor-
tant when analyzing effects of compo-
nents of dialysis treatment on survival,
because body size and dialysis prescrip-
tion normally are somewhat con-
founded: one main target of dialysis is
to achieve a minimum urea reduction
ratio. In small patients a given urea
reduction ratio can more easily be
achieved with a relatively short dialysis
session length; thus, smaller patients
and patients with low total body water
(such as women) typically will be
dialyzed for shorter periods than larger
patients and, especially, large men.
For reasons not yet clear, smaller
hemodialysis patients have a markedly
increased mortality. If no adjustment is
made for body size, when mortality is
found to be increased in patients
receiving shorter dialysis treatments, it
is not clear whether the effect is due to
treatment time alone or was partly or
completely mediated by body size. On
the other hand, it remains possible that
the shorter treatment time usually
given to smaller patients is causally
related to their increased mortality risk,
and in this case, adjusting the outcomes
analysis for body size might result in an
underestimation of the true risk of
shorter treatments.
The usual method of adjusting for
body size is to consider some measure of
body size, be it weight, anthropometric
estimates of total body water or body
surface area, volume, or body mass
index, as a covariate. Flythe et al.1 used
a matching strategy, in which patients of
a given size being prescribed a dialysis
time less than 4h were matched with
similar-sized patients being prescribed a
dialysis session longer than 4h. Secondary
matching by age, sex, and vascular access
type also was done. When mortality rates
in the less-than-4-hour and more-than-4-
hour groups were compared, there was a
very substantial difference in mortality,
with the group being prescribed less than
4h (mean delivered time, 201min) having
a 26% higher mortality than the size-
matched patients undergoing the
longer treatments (mean delivered
time, 240min).
The concept that dialysis time per se
might be an important measure of
dialysis adequacy, beyond urea reduc-
tion ratio or urea Kt/V, is an old idea
that has been rediscovered and is
gaining increasing traction. Because
urea is a small, highly diffusible mole-
cule, urea can be rapidly removed from
the body by high-efficiency dialysis.
This is true especially in smaller
patients, women, and children, in
whom the volumes of distribution of
urea are relatively small. With short,
rapid dialysis, however, it is more
difficult to remove partially seques-
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tered, larger molecules such as phos-
phate, as well as various candidate
middle molecules and protein-bound
substances. At the start of a dialysis
session, excess salt and water accumu-
lated during the interdialytic interval is
confined to tissue spaces and enters the
circulation slowly and often incomple-
tely during dialysis. Rapid fluid-re-
moval attempts can result in depletion
of the circulating volume and in
hypotension with ‘stunning’ of myo-
cardium and other organs. Both in-
tradialytic hypotension and incomplete
removal of salt and water with resulting
fluid overload are associated with
increased risk of death.2,3 The
potential benefits of longer dialysis
times have been documented in some
centers that provide dialysis schedules
of three times a week for 6–8 h
per session, given either during the
daytime or at night. Findings include
better control of blood pressure, de-
creased need for antihypertensive med-
ications, fewer intradialytic hypotensive
episodes, and in some studies, reduced
mortality.4 Thus, the results of Flythe
et al.1 are not inconsistent with current
concepts of optimal dialysis adequacy.
There are, however, several potential
concerns with the study of Flythe et al.1
The first is the issue of biologic
plausibility. It is somewhat surprising
that such a modest increase in the
dialysis session length on a percentage
basis (about 20%) would have a 26%
impact on survival. Although a high
ultrafiltration rate during dialysis has
been shown to have an adverse effect on
patient survival,5 in the two size-
matched groups, the mean difference
in ultrafiltration rate was less than 10%;
moreover, there was no evidence in the
more-than-4-hour group that volume
control was better (in terms of lower
pre- or postdialysis blood pressure),
that the frequency of intradialytic
hypotensive episodes was reduced, or
that phosphorus control was better, in
comparison with the size-matched
group receiving shorter treatments. To
be fair, the Dialysis Outcomes and
Practice Patterns Study (DOPPS)
group of investigators recently has
presented such data regarding better
intermediate volume and phosphorus
outcomes in patients undergoing
longer treatments,6 and better volume
control, especially, is almost certain to
occur with longer treatments.4
Another potential problem with
interpretation of the results of this
study is lack of internal consistency.
In their source population, the authors
provided data that mortality in patients
being dialyzed less than 4 h was only
8% higher (relative risk, 1.08) than that
in patients being dialyzed more than
4 h. Because the group being dialyzed
less than 4 h was enriched with smaller
patients, one would expect that adjust-
ing for body size in the usual way, as a
covariate, would have further reduced
this already small mortality risk of less-
than-4-hour dialysis. However, when
the size-matched subgroup analysis was
done, this small risk of less-than-4-
hour dialysis was not reduced, as
expected, but paradoxically magnified.
Thus, the size-matched subgroup re-
sults were not consistent with the
overall dialysis time results in the
population from which the size-
matched subgroup was drawn. Sec-
ondly, the benefit of a longer prescribed
dialysis session was monotonously si-
milar in small versus large patients and
in men versus women. One would have
expected an enhanced effect in smaller
patients and women. Yet another diffi-
cult-to-explain finding is the results of
a secondary analysis in which patients
were again matched on the basis of size
and other variables, but this time
into three groups, with prescribed
dialysis times of less than 210min,
210–240min, and more than 240min.
The mortality difference in the more-
than-240-min group was again lower by
the same degree, but there was abso-
lutely no difference in mortality between
the groups matched to get less than
210min and 210–240min of dialysis.
When all is said and done, when
dialysis time is zero, 1-year mortality
in patients with minimal residual
function should approach 100%, and
so the relationship between dialysis
time and mortality by definition should
be exponential. Thus, an exponential
magnification of risk would be ex-
pected when less-than-210-minute ses-
sions are compared with prescribed
treatment times of 210–240min; how-
ever, absolutely no increase in risk was
found with the size-matching strategy
used. These results suggest that there
was something very specific about the
240-minute prescribed dialysis time
threshold and suggest perhaps a reg-
ulatory or quality bias (see below)
active at the 240-minute time point
rather than a biologic adverse effect of
slightly shorter treatment times.
The benefits of longer dialysis time
found by Flythe et al.1 are not con-
sistent with randomized trials, where
increases in dialysis session length of
similar or greater magnitude failed to
improve survival (Table 1). For exam-
ple, the effect of dialysis time was one
of the two main intent-to-treat inter-
ventions in the randomized National
Cooperative Dialysis Study (NCDS).7
In the two longer time groups of the
NCDS, mean dialysis session lengths
were about 4.3 h, compared with 3.2 h
in two shorter time groups. The NCDS
was not powered to detect changes in
mortality; a benefit of longer time on
hospitalizations was found). In the
HEMO trial, dialysis time was an
integral part of the intent-to-treat dose
intervention; the requisite differences in
dialysis dose could not practically be
achieved by changes in dialyzer clearance
alone. In the intent-to-treat analysis of
the HEMO Study results,8 the mean
session-length differences between the
conventional and high-dose groups were
on the order of 30min, very similar to
the time difference found between the
two groups of the observational trial by
Flythe et al.;1 yet in the HEMO Study
intent-to-treat analysis, no benefit of
increased dose (which included time),
in terms of either survival or hospitali-
zations, was found.
In a conventional three-times-per-
week dialysis setting, data from other
observational studies regarding the effect
of time on survival are highly variable, to
the point that results sometimes point in
opposite directions. Table 1 summarizes
a few of these. In one study of incident
dialysis patients, Brunelli et al.9 found
opposite effects of time on survival,
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depending on whether time was assessed
as a baseline or a time-dependent cov-
ariate. Saran et al.,10 using the DOPPS
database, found that longer dialysis
sessions were indeed associated with
increased survival, but the effect was
enormously magnified in Japan and
somewhat magnified in Europe, com-
pared with results in US dialysis patients.
Moreover, a group that included some
of the same investigators11 recently
examined the effects of time on sur-
vival in a different set of US dialysis
patients and found the opposite
result—increased session length now
was associated with decreased survival.
Finally, Miller et al.,12 looking at patients
from the same large dialysis organi-
zation as the study by Flythe et al.,1
found no benefit in terms of survival of
dialysis sessions lasting longer than
3.5 h. This lack of consistency among
observational studies suggests that what
is being measured may be not a biologic
effect of dialysis session length, but
rather some confounding effect associated
with both mortality and dialysis time.
After the initial intent-to-treat ana-
lysis of the HEMO Study was reported,
as-treated associations between dialysis
dose and survival within each assigned
dose arm were analyzed.13,14 In contrast
to the negative intent-to-treat analysis,
within each treatment arm, delivered
dose was very powerfully associated
with survival. Both the denominator
(V) and the numerator (Kt) of dose
contributed to this effect, which was
termed ‘dose-targeting bias’ as it was
much too large to be explainable by a
biologic advantage of dose alone. Time,
a component of the numerator of
dialysis dose, had a marked effect on
survival in the high-dose arm of the
HEMO Study, and a much smaller
impact in the standard-dose arm,13,14
for reasons that remain unclear;
however, in the high-dose arm the
average urea reduction ratio of 75%
was quite similar to the average dose of
dialysis being delivered in the United
States today.13,14
Apart from body size, what could be
the explanations for how assignment
of a shorter or a longer dialysis session
length might be associated with
changes in patient survival (Figure 1)?
One prime candidate for confounding
is ‘regulatory,’ ‘quality,’ or financial bias,
perhaps best illustrated by the results of
Saran et al.,10 in which the benefits of a
more-than-4-hour treatment time were
magnified in Japan, a country where
nephrologists were paid extra for each
patient dialyzed for longer than 4 h.
Similarly, in many European countries,
regulations require that a certain per-
centage of patients in a given unit be
dialyzed longer than 4 h. The explana-
tion for such quality or regulatory bias
is a variant of the ‘good patient’ and/or
‘good nephrologist’ hypothesis: that
those patients not compliant with a
quality target have something asso-
ciated with them that is also linked to
increased mortality risk. Flythe et al.1
tried to get around such a ‘good
patient’ compliance bias by evaluating
prescribed, rather than delivered, dialysis
time, but there are not too many
nephrologists who will record a 4.5-
hour dialysis prescription for patients
who flatly refuse to dialyze longer than
3.5 h. In the United States, where regu-
latory and quality targets previously
focused on the urea reduction ratio, the
regulatory bias associated with longer
treatment times may have been less
pronounced in the past, but the recent
emphasis of large dialysis organizations
Table 1 | Effects of dialysis time on death risk in selected randomized and observational trials of conventional three-times-per-
week hemodialysis
Trial or chief author Reference Source of patients
Body-size
adjustment
Session length
analyzed as: Results/comments
Randomized trials
NCDS 7 NCDS (prevalent) None Intent-to-treat Not powered to detect change
in mortality (beneficial effect on
hospitalizations)
HEMO intent-to-treat 8 HEMO Study
(prevalent)
None or by weight Intent-to-treat (as part of
dose)
No effect of time (as part of
dose) on death risk or hospitali-
zations
Observational data
HEMO as treated
secondary analysis
13,14 HEMO Study
(prevalent)
Yes, covariate, Vant As-treated baseline and
time-dependent
Longer time-lower death risk
in high-dose treatment arm
DOPPS, Saran 10 DOPPS (various
countries, prevalent)
Yes, covariate, weight
and height
Time-dependent Longer time-lower death risk;
effect markedly greater in
Japan4Europe4US
Brunelli 9 LDO (incident) Yes, covariate, BMI Baseline
Time-dependent
Longer time-higher death risk
Longer time-lower death risk
Miller 12 LDO (prevalent) Yes, covariate, BMI Time-dependent No effect of time over 3.5 h
Ramirez 11 US government data-
base (prevalent)
Yes, covariate, Vant Baseline Longer time-higher death risk
Flythea 1 LDO (prevalent) Yes, matching,
weight
Baseline Longer time-lower death risk
Abbreviations: BMI, body mass index; DOPPS, Dialysis Outcomes and Practice Patterns Study; HEMO Study, Hemodialysis Study; LDO, large dialysis organization; NCDS,
National Cooperative Dialysis Study; Vant, anthropometric estimate of total body water.
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and end-stage renal disease networks
on achieving a certain minimum
dialysis time as a quality target may
be increasing the importance of a time-
associated regulatory bias in more
recently studied US patient cohorts.
In the as-treated HEMO Study
results, some of which are as yet
unpublished, we also found that, within
the high-dose arm, slight increases in
dialysis time during follow-up were
associated with marked increases in
survival, while slight decreases in time
were associated with increased mortal-
ity risk, even during periods of stable
vascular access. How can such a bias be
explained? Based on clinical experience,
one can concoct various scenarios,
most somewhat speculative; and some
explanations point in opposite direc-
tions. Several examples: Patients who
are noncompliant with the dialysis
prescription (who are known to have
poor survival) may refuse longer dia-
lysis times or may insist on shortening
dialysis session length as their course on
dialysis evolves. Dialysis session length
might be increased because of difficul-
ties with ultrafiltration, because of high
interdialytic weight gain, or because of
intradialytic hypotension. Time may be
increased in patients who are perceived
to be faring poorly. Longer dialysis time
may be prescribed for patients who
have lower amounts of residual func-
tion, or who have reduced blood flow
due to vascular access dysfunction or
who have accesses capable of only
limited blood flow.
Given the above difficulties, the
ability of observational studies to guide
us to an optimal dialysis prescription
remains limited. What, then, might be
possible ways forward? One potential
approach might be to work with
dialysis organizations that own large
numbers of dialysis units and that have
substantial control of medical practice
patterns within those units. Using this
infrastructure, one could design and
carry out randomized cluster trials,
where a shorter or longer dialysis time
is assigned to randomly chosen groups
of dialysis units with the use of an
intent-to-treat design. ‘Hard’ outcomes
such as mortality, hospitalizations, and
quality of life in each randomly as-
signed set of units could then be
ascertained, and the two groups could
be compared. Although at some level,
marked increases in dialysis time may
well be beneficial for most patients, I
believe that we will have to await the
outcome of such a randomized cluster
trial before we can validly calibrate the
extent of outcome benefit associated
with relatively modest increases in
dialysis session length in a three-times-
per-week setting. Lastly, the question of
whether or not higher predialysis serum
bicarbonate concentrations increase
mortality risk independent of nutri-
tional adjustment remains undefined;15
nevertheless, one needs to keep in
mind that long, high-efficiency dialysis
sessions against dialysates of high
base content, especially when given to
small patients, may increase pre- and
postdialysis serum bicarbonate levels
beyond an optimal range, and in such
cases dialysis efficiency and/or dialysate
base content may need to be adjusted
appropriately.
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Circulating Klotho levels: clinical
relevance and relationship with
tissue Klotho expression
Tilman B. Dru¨eke1 and Ziad A. Massy1,2
Klotho is a protein that exerts paracrine and endocrine functions.
In chronic kidney disease (CKD), its expression is decreased in several
tissues. This decrease probably plays important roles in various
complications associated with CKD, in both a fibroblast growth
factor-23 (FGF23)-dependent and an FGF23-independent manner.
The clinical diagnosis of Klotho deficiency is not easy. The relevance
of circulating Klotho levels, if any, needs to be adequately defined.
Serum Klotho may not reflect tissue Klotho concentration.
Kidney International (2012) 83, 13–15. doi:10.1038/ki.2012.370
The unraveling of the respective roles of
Klotho and fibroblast growth factor-23
(FGF23) occupies at present a major
place in both experimental and clinical
research devoted to the mineral and
bone disorder of chronic kidney disease
(CKD-MBD) and to disturbances of
bone and mineral metabolism in other
disease states.
Klotho, or more precisely a-Klotho,
is a single-pass transmembrane protein
that is expressed predominantly in
kidney tubular epithelium, and to a
lesser extent in the parathyroid gland
and epithelial cells of the choroid
plexus. The protein has a large extra-
cellular amino-terminal domain and a
small intracellular carboxy-terminal
domain. The extracellular domain is
made of two internal repeat sequences,
named KL1 and KL2.1 Circulating
Klotho results either from direct
secretion by the cell or from cleavage
of the intracellular domain of the full-
length protein by secretases. Both
processes lead to ‘soluble Klotho,’
which is found in blood, urine, and
cerebrospinal fluid.2
It was believed for some time that
Klotho functioned mainly, if not un-
iquely, as a coreceptor for FGF23
binding to FGF receptor 1 (FGFR1),
and that this cooperativity function was
restricted to the ectodomain of mem-
brane Klotho. Although FGFRs have a
much lower affinity for the isolated
Klotho ectodomain than for the full-
length transmembrane form, the rela-
tive importance of membrane and
soluble Klotho in this interaction re-
mains elusive.2 It is clearly established
at present that Klotho exerts both
FGF23-dependent and FGF23-indepen-
dent, pleiotropic actions. Soluble
Klotho acts as both a paracrine and
an endocrine factor.3
Its paracrine functions include reg-
ulation of the surface abundance of the
tubular Ca2þ channel TRPV5 and Kþ
channel ROMK in that Klotho is a
glycosidase removing sialic acids from
N-glycan.1 Notably, soluble Klotho also
has been shown to inhibit sodium
phosphate (NaPi) cotransporters in
renal opossum kidney cells and in
cell-free membrane vesicles in vitro in
the absence of FGF23. Moreover,
exogenously administered Klotho
resulted in decreased renal expression
of NaPi-2a and hypophosphatemia in
FGF23-null mice in vivo, demonstrating
that Klotho can induce hyperphos-
phaturia independently of FGF23.4
Finally, soluble Klotho also inhibits
intestinal NaPi-2b transporters, as
shown in NaPi-2b-expressing oocytes.5
As a hormone, Klotho targets
multiple remote tissues and organs.
These actions comprise anti-aging and
cardiovascular protective properties.
Klotho reduces oxidative stress by the
inhibition of insulin and insulin-
like growth factor-1 signaling path-
ways. It enhances endothelial nitric
oxide production and thereby improves
endothelium-dependent vasodilata-
tion.6 It is an endogenous inhibitor
of vascular calcification, as shown
in recent studies in vitro and in
CKD mice in vivo. Finally, it decreases
cell-surface abundance of the Ca2þ
channel TRPC6. This channel is
expressed in cardiac, glomerular, and
vascular smooth muscle cells and plays
an important role in the regulation of
vascular resistance and blood pressure.1
Since upregulation of TRPC6 is
implicated in the pathogenesis of
cardiac hypertrophy and glomerulo-
sclerosis, downregulation of its express-
ion by Klotho should be protective
against these disease conditions.
At the cellular level, the antioxidant
actions of Klotho include the induction
of resistance to H2O2 and suppression of
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